GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (ASX:BLT) » Definitions » Days Sales Outstanding

Benitec Biopharma (ASX:BLT) Days Sales Outstanding : 0.00 (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Benitec Biopharma Days Sales Outstanding?

Benitec Biopharma's average Accounts Receivable for the three months ended in Mar. 2024 was A$0.08 Mil. Benitec Biopharma's Revenue for the three months ended in Mar. 2024 was A$0.00 Mil.

The historical rank and industry rank for Benitec Biopharma's Days Sales Outstanding or its related term are showing as below:

ASX:BLT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.1   Med: 134.9   Max: 2815.71
Current: 2815.71

During the past 11 years, Benitec Biopharma's highest Days Sales Outstanding was 2815.71. The lowest was 3.10. And the median was 134.90.

ASX:BLT's Days Sales Outstanding is ranked worse than
97.87% of 893 companies
in the Biotechnology industry
Industry Median: 73.34 vs ASX:BLT: 2815.71

Benitec Biopharma's Days Sales Outstanding declined from Mar. 2023 (104.21) to Mar. 2024 (0.00).


Benitec Biopharma Days Sales Outstanding Historical Data

The historical data trend for Benitec Biopharma's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Days Sales Outstanding Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.87 220.04 279.68 64.93 140.13

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 104.21 757.38 - - -

Competitive Comparison of Benitec Biopharma's Days Sales Outstanding

For the Biotechnology subindustry, Benitec Biopharma's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Days Sales Outstanding falls into.



Benitec Biopharma Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Benitec Biopharma's Days Sales Outstanding for the fiscal year that ended in Jun. 2023 is calculated as

Days Sales Outstanding (A: Jun. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2022 ) + Accounts Receivable (A: Jun. 2023 )) / count ) / Revenue (A: Jun. 2023 )*Days in Period
=( (0.004 + 0.082) / 2 ) / 0.112*365
=0.043 / 0.112*365
=140.13

Benitec Biopharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding (Q: Mar. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Mar. 2024 )) / count ) / Revenue (A: Mar. 2024 )*Days in Period
=( (0.079 + 0.081) / 2 ) / 0*365 / 4
=0.08 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Benitec Biopharma  (ASX:BLT) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Benitec Biopharma Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (ASX:BLT) Business Description

Traded in Other Exchanges
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Benitec Biopharma (ASX:BLT) Headlines

From GuruFocus

John Rogers' Recent Trades

By Tiziano Frateschi Tiziano Frateschi 04-06-2016

Ariel Fund Quarterly Commentary From John Rogers

By Holly LaFon Holly LaFon 01-21-2016

Blount International Inc. (BLT) CEO Joshua L Collins buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 06-17-2010

John Rogers Increases Stake in Blount International

By Tiziano Frateschi Tiziano Frateschi 04-13-2015

Blount International Inc. (BLT) CEO International Inc Blount buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-01-2009

Bill Nygren's Oakmark Comments on Blount International

By Holly LaFon Holly LaFon 07-10-2012

John Rogers Exits Blount International in 1st Quarter

By David Goodloe David Goodloe 06-12-2016